Floatz logo

64Cu-LLP2A

Marginal Zone Lymphoma

Washington University School of MedicineEarly Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
73/ 100

Competitive context

105 Active assets in the Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

64Cu-LLP2A is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
C
Indicative ·
39 / 100
View asset →
lymphoplasmacytic lymphomaDormant
C
Indicative ·
38 / 100
View asset →
follicular lymphomaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →